Related Experiment Video
Updated: Mar 9, 2026
04:01
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
2.1K
Reprogramming ferroptosis in MDSCs: For state-dependent immunotherapy combinations
1Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Biochimica Et Biophysica Acta. Reviews on Cancer
|March 7, 2026
Summary
Targeting ferroptosis in myeloid-derived suppressor cells (MDSCs) can modulate antitumor immunity. Strategies include limiting immunosuppressive mediators during sublethal stress or inducing lethal ferroptosis to enhance immune activation and immunotherapy synergy.
Area of Science:
- Immunology
- Cancer Biology
- Cell Death Mechanisms
Background:
- Myeloid-derived suppressor cells (MDSCs) play a critical role in tumor immune evasion.
- Ferroptosis, a regulated form of cell death, impacts MDSC function and antitumor immunity.
- MDSC-mediated immunosuppression is context-dependent and influenced by ferroptotic stress.
Purpose of the Study:
- To review the role of MDSC ferroptosis in regulating antitumor immunity.
- To introduce the "ferroptosis immunomodulation window" concept for therapeutic targeting.
- To explore strategies for modulating MDSC ferroptosis to enhance cancer immunotherapy.
Main Methods:
- Review of existing literature on ferroptosis, MDSCs, and antitumor immunity.
- Analysis of metabolic pathways (ACOD1-itaconate-NRF2, ASAH2) influencing MDSC ferroptosis.
- Conceptual framework development for therapeutic intervention.
Main Results:
- Sublethal ferroptosis in MDSCs releases immunosuppressive mediators (PGE₂, oxidized phospholipids), dampening anti-tumor T-cell and NK cell functions.
- Disrupting specific metabolic pathways sensitizes MDSCs to ferroptosis.
- Inhibiting ASAH2 induces lethal ferroptosis in MDSCs, enhancing immune activation.
Conclusions:
- The "ferroptosis immunomodulation window" offers a dual strategy: limiting immunosuppressive mediators or inducing lethal ferroptosis.
- Targeting MDSC ferroptosis can overcome immunosuppression and synergize with immunotherapy.
- Further research is needed for targeted delivery systems to control MDSC ferroptosis.
Related Concept Videos
01:24Methods of Nuclear Reprogramming
2.2K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.2K
01:29Somatic to iPS Cell Reprogramming
2.8K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.8K
01:15Differentiation of Common Myeloid Progenitor Cells
4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K